Most Read Articles
Pearl Toh, 6 days ago
The tyrosine kinase inhibitor nintedanib significantly delayed progression of a wide range of fibrosing interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF) compared with placebo, according to the INBUILD* study presented at ERS 2019.
15 Jul 2018
New drug applications approved by US FDA as of 1 - 15 July 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
01 Nov 2018
The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.

PRoFeSs score reliably predicts poor outcomes in severe community-acquired pneumonia

11 Aug 2019

The PRoFeSs score―which includes the Charlson score, as well as levels of day 3 lactate, day 1 and day 3 procalcitonin, day 3 D-dimer, and day 1 brain-type natriuretic peptide (BNP)―can identify severe community-acquired pneumonia (SCAP) patients at high risk of poor outcomes 5 days after ICU admission, a recent study has found.

Researchers conducted a single-centre, prospective cohort study including 107 ICU patients (mean age, 62.0±15.7 years; 60.7 percent male) diagnosed with SCAP. The study’s primary outcome included death and the lack of ≥2-point improvements in scores in the Sequential Organ Failure Assessment within 5 days of treatment.

Six variables emerged as significantly predictive of the primary outcome. For instance, Charlson score (adjusted odds ratio [OR], 1.330, 95 percent CI, 1.059–1.669; p=0.021) and day 3 concentrations of D-dimer (adjusted OR, 2.185, 1.352–3.530; p=0.001) were strongly and positively correlated with the likelihood of the primary outcome.

The same was true for day 3 concentrations of procalcitonin (adjusted OR, 1.635, 0.993–4.692; p=0.016) and lactate (adjusted OR, 1.954, 1.093–3.498; p=0.03).

In comparison, day 1 levels of BNP (adjusted OR, 0.950, 0.901–1.001; p=0.047) and procalcitonin (adjusted OR, 0.572, 0.355–0.922; p=0.003) were significantly but inversely correlated with the primary outcome.

Consolidating all factors into one predictive model produced the PRoFeSs score, which had an area under the receiver operating characteristic curve of 0.81 (0.72–0.89). At a cutoff of 3 points, sensitivity and specificity are both maximized, yielding values of 79 percent and 71 percent, respectively.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
The tyrosine kinase inhibitor nintedanib significantly delayed progression of a wide range of fibrosing interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF) compared with placebo, according to the INBUILD* study presented at ERS 2019.
15 Jul 2018
New drug applications approved by US FDA as of 1 - 15 July 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
01 Nov 2018
The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.